一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Clinical Pharmacokinetics >>article
Clinical Pharmacokinetics

Clinical Pharmacokinetics

IF: 4.59
Download PDF

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.

Published:1 April 2023 DOI: 10.1007/s40262-023-01225-7 PMID: 37000342
T Y J Appeldoorn, T H Oude Munnink, L M Morsink, M N Lub-de Hooge, D J Touw

Abstract

Background and objective: Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Ruxolitinib is used to treat myelofibrosis, polycythemia vera and steroid-refractory graft-versus-host disease in the setting of allogeneic stem-cell transplantation. This review describes the pharmacokinetics and pharmacodynamics of ruxolitinib.

Methods: Pubmed, EMBASE, Cochrane Library and web of Science were searched from the time of database inception to march 15, 2021 and was repeated on November 16, 2021. Articles not written in English, animal or in vitro studies, letters to the editor, case reports, where ruxolitinib was not used for hematological diseases or not available as full text were excluded.

Results: Ruxolitinib is well absorbed, has 95% bio-availability, and is bound to albumin for 97%. Ruxolitinib pharmacokinetics can be described with a two-compartment model and linear elimination. Volume of distribution differs between men and women, likely related to bodyweight differences. Metabolism is mainly hepatic via CYP3A4 and can be altered by CYP3A4 inducers and inhibitors. The major metabolites of ruxolitinib are pharmacologically active. The main route of elimination of ruxolitinib metabolites is renal. Liver and renal dysfunction affect some of the pharmacokinetic variables and require dose reductions. Model-informed precision dosing might be a way to further optimize and individualize ruxolitinib treatment, but is not yet advised for routine care due to lack of information on target concentrations.

Conclusion: Further research is needed to explain the interindividual variability of the ruxolitinib?pharmacokinetic variables and to optimize individual treatment.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Ruxolitinib 941678-49-5 C17H18N6 460 suppliers $10.00-$2757.40
P450 3A4 40 suppliers Inquiry

Similar articles

IF:1.9

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

European Journal of Drug Metabolism and Pharmacokinetics Kyle John Wilby,etc Published: 1 June 2018
IF:4.6

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

Clinical Pharmacokinetics Ulrike Graefe-Mody, Silke Retlich,etc Published: 1 July 2012
平乡县| 长泰县| 得荣县| 峨边| 临海市| 海兴县| 安平县| 宜良县| 德保县| 曲沃县| 保靖县| 军事| 巴塘县| 宁城县| 漳州市| 墨玉县| 长治市| 潍坊市| 惠州市| 石棉县| 康马县| 昌宁县| 九龙城区| 横峰县| 章丘市| 即墨市| 临漳县| 金平| 娄底市| 许昌县| 泰宁县| 佳木斯市| 阳春市| 七台河市| 延川县| 乐平市| 双城市| 雷山县| 阿尔山市| 西昌市| 神木县|